Damora Therapeutics (DMRA) Amortization of Deferred Charges (2019 - 2026)
Damora Therapeutics (DMRA) posted Amortization of Deferred Charges of $63000.0 for Q1 2026, up 6200.0% on a QoQ basis from $1000.0 in Q4 2025, and up 2000.0% year-over-year from $3000.0 in Q1 2025.
Damora Therapeutics (DMRA) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Damora Therapeutics' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $63000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 2000.0% year-over-year to $63000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72000.0 (up 2.86% YoY) and the FY2025 annual result came in at $12000.0, down 92.5% from the prior year.
- Amortization of Deferred Charges was $63000.0 for Q1 2026 at Damora Therapeutics, up from $1000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $206000.0 in Q4 2023 and bottomed at -$59000.0 in Q4 2024.
- A 5-year average of $73176.5 and a median of $78000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2024 — Amortization of Deferred Charges slumped 128.64% — and 2026, when it surged 2000.0%.
- Damora Therapeutics' Amortization of Deferred Charges stood at $143000.0 in 2022, then jumped by 44.06% to $206000.0 in 2023, then slumped by 128.64% to -$59000.0 in 2024, then soared by 101.69% to $1000.0 in 2025, then jumped by 6200.0% to $63000.0 in 2026.
- Business Quant data shows DMRA's Amortization of Deferred Charges at $63000.0 in Q1 2026, $1000.0 in Q4 2025, and $5000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Damora Therapeutics | 1.03 Bn | 828.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63,000.00 |
| Mar 31, 2026 | 63,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 72,000.00 |
| Jun 30, 2024 | 72,000.00 |
| Mar 31, 2024 | 93,000.00 |
| Mar 31, 2024 | 93,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Dec 31, 2023 | 206,000.00 |